HEALTH OF WOMAN. 2020.9-10(155-156): 76-82

Приналежність
1. West China Hospital, Sichuan University, Chengdu, Sichuan, China.
2. Clinical Research Centre, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
3. West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
4. University of Pittsburgh Medical Center, University of Pittsburgh, Pittsburgh, PA, USA.
5. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
6. Department of Surgery, Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.

ЛІТЕРАТУРА

1. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ (Clinical research ed). 1997 Jul 5;315(7099):32-4.

2. Mesiano S, Wang Y, Norwitz ER. Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? Reproductive sciences (Thousand Oaks, Calif). 2011 Jan;18(1):6-19.

3. Verhaegen J, Gallos ID, van Mello NM, Abdel-Aziz M, Takwoingi Y, Harb H, et al. Accuracy of single progesterone test to predict early pregnancy outcome in women with pain or bleeding: meta-analysis of cohort studies. BMJ (Clinical research ed). 2012 Sep 27;345:e6077.

4. Gerhard I, Gwinner B, Eggert-Kruse W, Runnebaum B. Double-blind controlled trial of progesterone substitution in threatened abortion. Biological research in pregnancy and perinatology. 1987;8(1 1ST Half):26-34.

5. Palagiano A, Bulletti C, Pace MC, D DEZ, Cicinelli E, Izzo A. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann N Y Acad Sci. 2004 Dec;1034:200-10.

6. Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Mol Biol 2005;97:421-5.

7. El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas 2009;65 Suppl 1:S43-S46.

8. Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas 2009 Dec;65 Suppl 1:S47-50.

9. Alimohamadi S, Javadian P, Gharedaghi MH, Javadian N, Alinia H, Khazardoust S, et al. Progesterone and threatened abortion: a randomized clinical trial on endocervical cytokine concentrations. J Reprod Immunol 2013 Jun;98 (1-2):52-60.

10. Yassaee F, Shekarriz-Foumani R, Afsari S, Fallahian M. The effect of progesterone suppositories on threatened abortion: a randomized clinical trial. J Reprod Infertil 2014;15 (3):147-51.

11. Turgal M, Aydin E, Ozyuncu O. Effect of micronized progesterone on fetal-placental volume in first-trimester threatened abortion. J Clin Ultrasound 2017;45 (1):14-9.

12. Lee HJ, Park TC, Kim JH, Norwitz E, Lee B. The influence of oral dydrogesterone and vaginal progesterone on threatened abortion: a systematic review and meta-analysis. BioMed Research International. 2017;2017:3616875.

13. Wahabi HA, Fayed AA, Esmaeil SA, BahkaliKH. Progestogen for treating threatened miscarriage. The Cochrane Database of Systematic Reviews. 2018 Aug 6;8:CD005943.

14. Gynecologists ACoOa. ACOG practice bulletin-clinical management guidelines for obstetricians-gynecologists: early pregnancy loss. May 2015: https://www.acog.org/-/media/Practice-Bulletins/Committee-on-Practice-Bulletins—-Gynecology/ Public/pb150.pdf

15. Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, et al. A randomized trial of progesterone in women with bleeding in early pregnancy. The New England journal of medicine. 2019 May 9;380(19):1815-24.

16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine. 2009 Aug 18;151 (4):W65-94.

17. Shinichi A. Cochrane handbook for systematic reviews of interventions. Online Kensaku 2014;35 (3):154-5.

18. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed). 2008 Apr 26;336 (7650):924-6.

19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002 Jun 15;21 (11):1539-58.

20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed ). 1997 Sep 13;315 97109):629-34.

21. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008 Aug;61 (8):763-9.

22. Ehrenskjold ML, Bondo B, Weile F. Treatment of threatened abortion with dydrogesterone. Ugeskr Laeger 1967 Dec 14;129 (50):1678-9.

23. Czajkowski K, Sienko J, Mogilinski M, Bros M, Szczecina R, Czajkowska A. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril 2007 Mar;87 (3):613-8.

24. Vincze E, Molna´rGB, Fo¨ldesiPlA. Treatment possibilities for threatened abortion using progesterone and progesterone-type drugs. Magyar Noorvosok Lapja 2006;69:281-4.

25. Siew JYS, Allen JC, Hui CYY, Ku CW, Malhotra R, Ostbye T, et al. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage. Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:319-24.

26. Darwish A. Enhancing Success of Assisted Reproduction. Rijeka: InTech. 2012:155-72.

27. Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecological 
endocrinology: the official journal of the International Society of Gynecological Endocrinology. 2016;32(2):97-106.

28. Merriam KS, Leake KA, Elliot M, Matthews ML, Usadi RS, Hurst BS. Sexual absorption of vaginal progesterone: a randomized control trial. Int J Endocrinol 2015;2015:685281.